{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-009853","form_type":"8-K","ticker":"ACRS","cik":"0001557746","company_name":"Aclaris Therapeutics, Inc.","filed_at":"2024-07-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.502249+00:00","generated_at":"2026-05-31T20:29:43.005335+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aclaris sells OLUMIANT royalties to OMERS for up to $31.5M upfront and milestones","bullets":["Received $26.5M upfront; eligible for up to $5M additional based on 2024 sales milestones for OLUMIANT.","Sold portion of future OLUMIANT royalties from Lilly and 100% of remaining anniversary milestone payments.","Non-dilutive transaction; proceeds to strengthen balance sheet and support strategic priorities.","Aclaris continues strategic review; will invest in internal immuno-inflammatory pipeline programs.","OLUMIANT (baricitinib) is Lilly's treatment for alopecia areata; royalty term runs through remainder of license."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-009853","json":"https://secwatch.observer/filing/0001558370-24-009853.json","markdown":"https://secwatch.observer/filing/0001558370-24-009853.md","text":"https://secwatch.observer/filing/0001558370-24-009853.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1557746/000155837024009853/0001558370-24-009853-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1557746/000155837024009853/acrs-20240716x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T20:29:43.005335+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}